Kaijin Xu

12.8k total citations · 3 hit papers
113 papers, 5.9k citations indexed

About

Kaijin Xu is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Kaijin Xu has authored 113 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Infectious Diseases, 56 papers in Epidemiology and 24 papers in Hepatology. Recurrent topics in Kaijin Xu's work include COVID-19 Clinical Research Studies (23 papers), Tuberculosis Research and Epidemiology (22 papers) and Hepatitis B Virus Studies (19 papers). Kaijin Xu is often cited by papers focused on COVID-19 Clinical Research Studies (23 papers), Tuberculosis Research and Epidemiology (22 papers) and Hepatitis B Virus Studies (19 papers). Kaijin Xu collaborates with scholars based in China, United States and Singapore. Kaijin Xu's co-authors include Lanjuan Li, Jifang Sheng, Hongliu Cai, Yunqing Qiu, Yi‐Yan Yang, Huaying Wang, Xiaowei Xu, Weimin Fan, Hainv Gao and Xiaoxin Wu and has published in prestigious journals such as SHILAP Revista de lepidopterología, ACS Nano and Gastroenterology.

In The Last Decade

Kaijin Xu

111 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

2020 1.5k citations Xiaowei Xu, Xiaoxin Wu et al. BMJ profile →
Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent

2009 561 citations Kaijin Xu, Lanjuan Li et al. profile →
Biodegradable nanostructures with selective lysis of microbial membranes

2011 529 citations Kaijin Xu, Lanjuan Li et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kaijin Xu China	32	2.4k	1.3k	1.0k	943	811	113	5.9k
Ali A. Rabaan Saudi Arabia	43	3.1k 1.3×	1.5k 1.2×	1.1k 1.1×	647 0.7×	208 0.3×	308	7.7k
Huimin Xia China	41	1.1k 0.4×	2.6k 2.1×	634 0.6×	623 0.7×	79 0.1×	294	7.3k
Charles S. Dela Cruz United States	41	1.5k 0.6×	3.7k 2.9×	1.3k 1.3×	559 0.6×	256 0.3×	158	9.9k
Gheyath K. Nasrallah Qatar	42	1.3k 0.5×	1.6k 1.3×	779 0.8×	197 0.2×	85 0.1×	174	6.5k
Jason Kindrachuk Canada	33	1.7k 0.7×	1.6k 1.3×	582 0.6×	290 0.3×	1.4k 1.7×	89	5.0k
Jin Soo Lee South Korea	50	925 0.4×	2.3k 1.8×	1.6k 1.6×	237 0.3×	146 0.2×	345	9.8k
Hong Zhao China	33	1.4k 0.6×	1.5k 1.1×	907 0.9×	765 0.8×	30 0.0×	141	4.6k
Xi Huang China	44	2.1k 0.9×	2.9k 2.2×	1.1k 1.1×	296 0.3×	490 0.6×	194	10.8k
Meng Xiao China	41	2.5k 1.1×	1.1k 0.9×	2.0k 2.0×	326 0.3×	235 0.3×	264	5.7k
Holger F. Rabenau Germany	43	4.4k 1.9×	979 0.8×	2.2k 2.2×	289 0.3×	184 0.2×	220	7.9k

Countries citing papers authored by Kaijin Xu

Since Specialization

Citations

This map shows the geographic impact of Kaijin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaijin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaijin Xu more than expected).

Fields of papers citing papers by Kaijin Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaijin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaijin Xu. The network helps show where Kaijin Xu may publish in the future.

Co-authorship network of co-authors of Kaijin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Kaijin Xu. A scholar is included among the top collaborators of Kaijin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaijin Xu. Kaijin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Wanru, Zhongkang Ji, Ruihong Zhao, et al.. (2025). Nontuberculous Mycobacterial Pneumonia Caused by Mycobacterium immunogenum: A Case Report and Literature Review. Infection and Drug Resistance. Volume 18. 1859–1865.

Cao, Dan, Tiantian Wu, Zhongkang Ji, et al.. (2024). Antimicrobial and Antibiofilm Effects of Bithionol against Mycobacterium abscessus. Antibiotics. 13(6). 529–529. 1 indexed citations

Hu, Wenjuan, Xiaomeng Li, Wanru Guo, et al.. (2024). The Utility of Real-Time PCR, Metagenomic Next-Generation Sequencing, and Culture in Bronchoalveolar Lavage Fluid for Diagnosis of Pulmonary Aspergillosis. Journal of Molecular Diagnostics. 26(9). 832–842. 4 indexed citations

Wu, Tiantian, et al.. (2023). The type III secretion system facilitates systemic infections of Pseudomonas aeruginosa in the clinic. Microbiology Spectrum. 12(1). e0222423–e0222423. 6 indexed citations

Xia, Jiafeng, Wanru Guo, Ming Hu, et al.. (2023). Resynchronized rhythmic oscillations of gut microbiota drive time-restricted feeding induced nonalcoholic steatohepatitis alleviation. Gut Microbes. 15(1). 2221450–2221450. 31 indexed citations

Xia, Jiafeng, Longxian Lv, Boqiang Liu, et al.. (2022). Akkermansia muciniphila Ameliorates Acetaminophen-Induced Liver Injury by Regulating Gut Microbial Composition and Metabolism. Microbiology Spectrum. 10(1). e0159621–e0159621. 121 indexed citations

Lü, Juan, Jing Guo, Jun Liu, Xiaomin Mao, & Kaijin Xu. (2022). Long Non-coding RNA MALAT1: A Key Player in Liver Diseases. Frontiers in Medicine. 8. 734643–734643. 27 indexed citations

Xu, Xiaolan, Lushun Jiang, Liya Pan, et al.. (2021). Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049. International Journal of Health Policy and Management. 11(10). 2115–2123. 5 indexed citations

Guo, Wanru, et al.. (2021). Glycan Nanostructures of Human Coronaviruses. International Journal of Nanomedicine. Volume 16. 4813–4830. 7 indexed citations

10.

Fang, Hong, et al.. (2020). Risk factors for negative T-SPOT.TB assay results in patients with confirmed active tuberculosis: A retrospective study. The Journal of Infection in Developing Countries. 14(11). 1288–1295. 7 indexed citations

11.

Ni, Qin, Cheng Ding, Yongtao Li, et al.. (2020). Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia. 13(6). 9 indexed citations

12.

Ji, Zhongkang, Hong Fang, Shuting Wang, et al.. (2020). Faropenem Susceptibility of Multidrug-resistant Contemporary Clinical Isolates from Zhejiang Province, China. SHILAP Revista de lepidopterología. 2(1). 26–29. 6 indexed citations

13.

Qiu, Yan, et al.. (2020). WeChat-based health education to improve health knowledge in three major infectious diseases among residents: a multicentre case-controlled protocol. BMJ Open. 10(11). e037046–e037046. 5 indexed citations

14.

Ni, Qin, Cheng Ding, Yongtao Li, et al.. (2020). Effect of low-to-moderate dose glucocorticoids on viral clearance in COVID-19: a retrospective study. 13(1). 21–24. 4 indexed citations

15.

Xu, Xiaowei, Xiaoxin Wu, Xiangao Jiang, et al.. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 368. m606–m606. 1497 indexed citations breakdown →

16.

Wu, Jie, Shigui Yang, Kaijin Xu, et al.. (2018). Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983–2007) and Predictions to 2030. Gastroenterology. 154(6). 1719–1728.e5. 69 indexed citations

17.

Yang, Shigui, Cheng Ding, Yuanxia Cui, et al.. (2017). Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open. 7(4). e014947–e014947. 18 indexed citations

18.

Yao, Jun, Jing Li, Zhenggang Jiang, et al.. (2015). Suitable hepatitis B vaccine for adult immunization in China. Immunologic Research. 64(1). 242–250. 5 indexed citations

19.

Yu, Chengbo, et al.. (2014). The serum IL ‐23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B. Liver International. 35(5). 1549–1556. 9 indexed citations

20.

Xing, Huichun, Lanjuan Li, Kaijin Xu, et al.. (2004). Intestinal microflora in rats with ischemia/reperfusion liver injury. Journal of Zhejiang University SCIENCE B. 6(1). 14–21. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact